Navigation Links
Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
Date:5/25/2010

aken by patients who have advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; known hypersensitivity or idiosyncrasy to sympathomimetic amines; agitated states; glaucoma; a history of drug abuse; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.  Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD.  Physicians should take a careful patient history, including family history, and physical exam, to assess the presence of cardiac disease.  Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated.  Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.

New psychosis, mania, aggression, growth suppression, visual disturbances and exacerbation of tics and Tourette's syndrome have been associated with the use of stimulants.  Use with caution in patients with a history of psychosis, seizures or EEG abnormalities, bipolar disorder, or depression.  Growth should be monitored in children during treatment with stimulants, and patients who are not growing (gaining height or weight) as expected may need to have their treatment interrupted.

The most common adverse reactions (greater than or equal to 5 percent and at least twice the rate of placebo) reported in the pivotal clinical trials were pediatric – decreased appetite, insomnia, upper abdominal pain, irritability, decreased weight, vomiting, nausea, dizziness and dry mouth; adult
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... and SOUTH SAN FRANCISCO, Calif. ... the venture arm of Baxter International Inc. (NYSE: ... LLC ("VPD") today announced the formation of Vitesse Biologics, ... by Baxter Ventures to focus on the development of ... hematology, and oncology. Following the spin-off of Baxter BioScience ...
(Date:6/1/2015)... /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") today ... the ERA-EDTA Congress in London, England ... First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects ... (CKD); a Post-hoc Analysis of Patients from the ASSERT, ... Kam Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension ...
(Date:6/1/2015)... , June 1, 2015   Epic Sciences, ... develops products and offerings to personalize and advance the ... has expanded the available credit under its existing credit ... amended agreement increases the available capacity of the facility ... the maturity by 27 months to April 1, 2019. ...
(Date:6/1/2015)... , May 29, 2015 Research ... the addition of the "2015 Strategies ... report to their offering. This ... European immunoprotein diagnostic market, including emerging tests, ... strategic profiles of leading suppliers. ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Two-dimensional, "sheet-like" nanostructures are commonly employed in biological ... properties have inspired interest in materials such as ... largest two-dimensional polymer crystal self-assembled in water to ... complexity of biological systems with the durable architecture ...
... ... Footprint , ... -- LS9, Inc ., the Renewable Petroleum Company™, today announced that its UltraClean ... was officially registered by the United States Environment Protection Agency (EPA). As a ...
... new method for identifying genetic variation, including mutations, in ... an important research tool that will lead to the ... method, which is directly applicable to cell preparations and ... genetic variation in patient samples from a variety of ...
Cached Biology Technology:Berkeley Lab scientists create 'molecular paper' 2LS9's UltraClean Diesel™ Receives EPA Registration 2Mutations directly identifiable in active genes 2
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Michigan researchers have discovered how to measure the ... cancer cells, a breakthrough that will revolutionize scientists' ... environment. , A team led by U-M ... multi-walled carbon nanotubes---one of the most promising nanomaterials ...
... Biotechnology, scientists and doctors with the Physicians Committee for ... to grow live cells in the laboratory. At issue ... obtained by puncturing the heart of a fetal calf ... cells in a medium free of animal serum, enabling ...
... have discovered that our ears use the most efficient ... brooks to wailing babies. These results represent a significant ... for transmission to the brain, according to the authors, ... Views" editorial in the Feb. 23 issue of Nature. ...
Cached Biology News:Carbon nanotube absorption measured in worms, cancer cells 2Carnegie Mellon scientists show brain uses optimal code for sound 2Carnegie Mellon scientists show brain uses optimal code for sound 3
Buffer used for mitocapture assays....
... CyScribe GFX Purification Kit, 25 ... CyDye labeled cDNA probesProvides efficient removal ... from labeling reactions with superior yields ... for the purification of cDNA labeled ...
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Biology Products: